| Sep 24 |
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
|
| Sep 23 |
Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
|
| Sep 20 |
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
|
| Sep 9 |
Aditxt and Evofem amend merger agreement
|
| Sep 9 |
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
|
| Sep 6 |
Aditxt files to sell $150M of common stock
|
| Sep 4 |
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
|
| Aug 29 |
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
|
| Aug 26 |
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
|
| Aug 21 |
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
|
